// startup autopsy
Cavis Microcaps
Microscale drug delivery ambitions dissolved without pharma partners.
marketfitSilent Shutdown
Quiet closure with no public announcement · Fatal mistake: Pursued independent clinical development of microencapsulation technology without securing pharma licensing deals that could have extended runway and validated commercial interest.
Key Events Timeline
FOUNDING
Cavis Microcaps founded in Germany to develop microencapsulation technology for pharmaceutical drug delivery applications.
PRODUCT LAUNCH
Demonstrated proof-of-concept microencapsulation platform to potential pharma partners at industry conferences.
FUNDING
Secured $5M in funding to advance microencapsulation technology toward clinical validation and pharma licensing.
PIVOT
Shifted strategy to pursue direct licensing deals with European pharma companies after independent development costs exceeded projections.
SHUTDOWN
Cavis Microcaps closed after exhausting funding without securing the pharma partnerships needed for commercial viability.